Trillium Therapeutics shares soar on Pfizer’s $2.26B deal
Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.
Monday, August 23, 2021
Trillium Therapeutics shares soar on Pfizer’s $2.26B deal
Trillium Therapeutics shares soar on Pfizer’s $2.26B deal
Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.
Related Posts:
0 comments:
Post a Comment